- HS-20136-2 features highly potent insulinotropic activity, unique GIPR biased signaling and robust preclinical anti-obesity efficacy.
- The ongoing clinical development of HS-20136-2 is progressing as planned. As a differentiated QM GLP-1R/GIPR/GCGR agonist, it has the potential to expand therapeutic options for patients.
SHANGHAI, November 16, 2026 — Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma"; 03692.HK) today announced that, in a Late-Breaking Abstract poster at ObesityWeek® 2026 (the 44th Annual Meeting of The Obesity Society, TOS), it presented results from preclinical studies of HS-20136-2, a novel once monthly subcutaneous glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/glucagon (GCG) Triple Receptor Agonist[1].
Details of the Poster Presentation Are as Follows:
Title: Discovery of HS-20136-2: A Novel Once Monthly Subcutaneous GLP-1/GIP/GCG Triple Receptor Agonist for the Treatment of Metabolic Disorders
Session: Gut Peptides, Appetite Signaling & Novel Therapeutics
Abstract No.: Poster-242
Date/Time: 11/14/2026, 7:30 pm - 8:30 pm (EST)
Presenter: Ting Wang, Hansoh Pharma
Method:
This study employed a systematic evaluation framework spanning in vitro pharmacology, in vivo pharmacokinetics, and in vivo efficacy to comprehensively characterize the candidate's pharmacological profile.
Results:
• Receptor Agonism: HS-20136 showed slightly reduced cAMP potency at GLP-1R and GCGR but marginally enhanced activity at GIPR versus endogenous ligands under 0.1% casein conditions. In 100% human plasma, it was approximately 5-fold more potent than Retatrutide at GLP-1R and GCGR, with comparable potency at GIPR.
• Biased Agonism: HS-20136 exhibited a distinct GIPR signaling bias, with 60% lower β-arrestin-2 recruitment than Retatrutide, potentially reducing receptor desensitization and supporting sustained GIPR signaling.
• Glucose-Stimulated Insulin Secretion (GSIS): In human EndoC-βH5 cells, HS-20136 enhanced GSIS by 3.11-fold, with an EC₅₀ of 0.82 nM, exhibiting 3.3-fold higher GSIS potency than Retatrutide.
• In formulation development, HS-20136-2 employed Hansoh’s proprietary long-acting sustained-release technology to establish a subcutaneous drug depot, enabling gradual and sustained drug release. In non human primates,(NHP), HS-20136-2 can delay absorption rate and achieve steady drug release without burst release in one month, with Cmax/C672h ratio=1.8 after single subcutaneous dose of 0.5 mg/kg, supporting the once-monthly (QM) dosing regimen in clinical development.
• In DIO SD rats, a single administration of HS-20136-2 produced marked, sustained dose-dependent body weight loss, together with reduced food intake, demonstrating favorable preclinical anti-obesity efficacy.
These preclinical findings provide a pharmacological and pharmacokinetic rationale for the once-monthly subcutaneous regimen and for the exploration of clinical dosing regimens with longer intervals. If this dosing profile is confirmed in human studies, such regimens may reduce dosing frequency, enhance the convenience of long-term treatment, and improve patient adherence, offering a potential option for the long-term management of obesity and related metabolic disorders.
Based on the above preclinical findings, Hansoh Pharma has initiated Phase 1 clinical studies of HS-20136-2 in Australia and China to evaluate its safety and tolerability, as well as its pharmacokinetic (PK) and pharmacodynamic (PD) profiles in humans.
About HS-20136-2
HS-20136-2 is a novel unimolecular GLP-1R/GIPR/GCGR triagonist developed via Hansoh’s proprietary long-acting platform, designed to achieve coordinated activation of all three targets through a differentiated molecular design and receptor-signaling strategy. It demonstrates potent metabolic regulatory activity and robust insulinotropic effects, while its biased GIPR agonism may improve gastrointestinal tolerability. HS-20136-2 has demonstrated a favorable preclinical pharmacokinetic profile, supporting its potential for once-monthly subcutaneous administration and offering a potential new treatment option for patients with obesity, overweight, or hyperglycemia. Phase 1 clinical studies of HS-20136-2 have been initiated in China and Australia in participants with obesity or overweight to further evaluate its safety, tolerability, and pharmacokinetic profile.
About Obesity
Obesity is a complex chronic disease driven by multiple factors. Currently, more than 650 million adults worldwide are affected, and the World Health Organization (WHO) has long recognized obesity as a major global public health epidemic requiring urgent action. According to data from 2025, the combined prevalence of overweight and obesity among adults in China has exceeded 50%[2] . As a major risk factor for a range of chronic conditions, obesity significantly increases the risk of type 2 diabetes, cardiovascular diseases and certain cancers, posing a substantial challenge to public health.
References:
1. Wang T, Sun DC, Yang XL, et al. Discovery of HS-20136-2: A Novel Once-Monthly Subcutaneous GLP-1/GIP/GCG Triple Receptor Agonist. Presented at: ObesityWeek®2026; Washington, DC. Poster 242.
2. World Obesity Federation. World Obesity Atlas 2025. Overweight, obesity and non-communicable diseases. New global, regional and national estimates of the prevalence of overweight and obesity in adults from 2000 to 2030. Mar, 2025. https://s3-eu-west-1.amazonaws.com/wof-files/World_Obesity_Atlas_2025_rev1.pdf
About Hansoh Pharma
Statements
Forward-Looking Statements